Bevacizumab plus irinotecan in recurrent glioblastoma - Reply

被引：4
|
作者：
Vredenburgh, James J. [1 ]
Desjardins, Annick
Reardon, David A.
Friedman, Henry S.
机构：
[1] Duke Univ, Med Ctr, Preston Robert Tisch Brain Tumor Ctr, Durham, NC 27710 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 06期
关键词：
D O I：
10.1200/JCO.2007.15.1746
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1013 / 1013
页数：1
相关论文
共 50 条
  • [21] Bevacizumab (BV) plus irinotecan (I) in recurrent glioblastoma multiforme (GBM): A single center experience.
    Iruarrizaga, Eluska
    Azkona, Eider
    Aresti, Unai
    Rubio, Itziar
    Arruti, Mikel
    Carrera, Sergio
    Fuente, Natalia
    Marrodan, Ines
    Lopez Escola, Cristina
    Condori, Elizabeth
    Manel Mane, Joan
    Lopez-Vivanco, Guillermo
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [22] Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab na⟨ve, recurrent glioblastoma
    Reardon, David A.
    Desjardins, Annick
    Peters, Katherine B.
    Gururangan, Sridharan
    Sampson, John H.
    McLendon, Roger E.
    Herndon, James E., II
    Bulusu, Anuradha
    Threatt, Stevie
    Friedman, Allan H.
    Vredenburgh, James J.
    Friedman, Henry S.
    JOURNAL OF NEURO-ONCOLOGY, 2012, 107 (01) : 155 - 164
  • [23] Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma
    David A. Reardon
    Annick Desjardins
    Katherine B. Peters
    Sridharan Gururangan
    John H. Sampson
    Roger E. McLendon
    James E. Herndon
    Anuradha Bulusu
    Stevie Threatt
    Allan H. Friedman
    James J. Vredenburgh
    Henry S. Friedman
    Journal of Neuro-Oncology, 2012, 107 : 155 - 164
  • [24] Retrospective analysis of patterns of recurrence seen on MRI in patients with recurrent glioblastoma multiforme treated with bevacizumab plus irinotecan
    Zuniga, R. M.
    Torcuator, R.
    Doyle, T.
    Anderson, J.
    Jain, R.
    Orley, J.
    Rosenblum, M.
    Mikkelsen, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [25] B BEVACIZUMAB ALONE VERSUS BEVACIZUMAB PLUS IRINOTECAN IN PATIENTS WITH RECURRENT GLIOBLASTOMA: A NATION-WIDE POPULATION-BASED STUDY
    Kim, S.
    Lee, Y.
    Lee, E.
    Roh, T.
    NEURO-ONCOLOGY, 2024, 26
  • [26] Long-term efficacy of bevacizumab and irinotecan in recurrent pediatric glioblastoma
    Umeda, Katsutsugu
    Shibata, Hirofumi
    Saida, Satoshi
    Hiramatsu, Hidefumi
    Arakawa, Yoshiki
    Mizowaki, Takashi
    Nishiuchi, Ritsuo
    Adachi, Souichi
    Heike, Toshio
    Watanabe, Ken-Ichiro
    PEDIATRICS INTERNATIONAL, 2015, 57 (01) : 169 - 171
  • [27] Tumor perfusion during bevacizumab and irinotecan in recurrent glioblastoma: A multimodal approach
    Eoli, M.
    Di Stefano, A.
    Aquino, D.
    Scotti, A.
    Anghileri, E.
    Cuppini, L.
    Prodi, E.
    Finocchiaro, G.
    Bruzzone, M. G.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S32 - S32
  • [28] A phase I trial of vorinostat in combination with bevacizumab and irinotecan in recurrent glioblastoma
    Chinnaiyan, P.
    Chowdhary, S.
    Brem, S.
    Yu, M.
    Murtagh, R.
    Rojiani, A.
    Tsai, Y.
    Pan, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [29] TUMOR PERFUSION DURING BEVACIZUMAB AND IRINOTECAN IN RECURRENT GLIOBLASTOMA: A MULTIMODAL APPROACH
    Eoli, Marica
    Di Stefano, Anna Luisa
    Aquino, Domenico
    Scotti, Alessandro
    Anghileri, Elena
    Cuppini, Lucia
    Prodi, Elena
    Finocchiaro, Gaetano
    Bruzzone, Maria Grazia
    NEURO-ONCOLOGY, 2013, 15 : 196 - 196
  • [30] Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy
    Reardon, David A.
    Desjardins, Annick
    Peters, Katherine B.
    Vredenburgh, James J.
    Gururangan, Sridharan
    Sampson, John H.
    McLendon, Roger E.
    Herndon, James E., II
    Coan, April
    Threatt, Stevie
    Friedman, Allan H.
    Friedman, Henry S.
    CANCER, 2011, 117 (23) : 5351 - 5358
12345